Clinical Trial Update: CT Antigen TCR-redirected T Cells for Ovarian Cancer. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/Phase 2 trial evaluating TCR-redirected T cells targeting CT antigen for ovarian cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• TCR-redirected T cells targeting CT antigen

Snippet

Sponsor: Adaptimmune | Conditions: Ovarian Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-01-03